REVELATION BIOSCIENCES, INC. 8-K

What Happened
Revelation Biosciences, Inc. (REVB) announced its financial results for the three months ended March 31, 2026 via a press release dated May 7, 2026. The company furnished that press release as Exhibit 99.1 to Form 8-K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Date filed: May 7, 2026 (Form 8-K reporting results for the quarter ended March 31, 2026).
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; press release furnished as Exhibit 99.1.
• Exhibits: Exhibit 99.1 = press release dated May 7, 2026; Exhibit 104 = Inline XBRL cover page data file.
• Signature: Report signed by Chester S. Zygmont, III, Chief Financial Officer (principal financial and accounting officer).

Why It Matters
This 8-K signals the company has publicly released its latest quarterly financial results; investors should review the attached press release (Exhibit 99.1) for revenue, earnings, guidance, and other financial metrics. The filing itself is routine disclosure of results and does not indicate any executive change or corporate action beyond the earnings release.